4.4 Article

2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features

期刊

ARTHRITIS CARE & RESEARCH
卷 63, 期 4, 页码 465-482

出版社

WILEY
DOI: 10.1002/acr.20460

关键词

-

资金

  1. American College of Rheumatology
  2. University of Alabama at Birmingham Deep South Musculoskeletal Center for Education and Research on Therapeutics (Agency for Healthcare Research and Quality) [U18-HS016956]
  3. NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2-RR025776-03]
  4. Merck
  5. Lilly
  6. Novartis
  7. PG
  8. Aventis
  9. Genentech
  10. Takeda
  11. AstraZeneca
  12. Horizon
  13. Bristol-Myers Squibb
  14. Roche

向作者/读者索取更多资源

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据